

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Katherine Galvin and Laura
A. Rudolph-Owen

Serial No.: 09/635,521

Filed: August 9, 2000

For: *METHODS AND COMPOSITIONS FOR THE
DIAGNOSIS AND TREATMENT OF
CARDIOVASCULAR AND TUMORIGENIC
DISEASE USING 4941*

Attorney Docket No.: MNI-094

Group Art Unit: 1636

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

1/24/01
Date of Signature and of Mail Deposit

By: 

Amy E. Mandragouras
Registration No. 36,207
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicants and their attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A full copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Amy E. Mandragouras
Registration No. 36,207
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: 1/24/01

GAD/AEM/MCL/JSH/mlh/lak
Enclosures

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MNI-094	SERIAL NO. 09/635,521
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Katherine Galvin and Laura A. Rud Iph-Owen	
		FILING DATE August 9, 2000	GROUP 1636

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

A1	Anderson, Everett et al. "Cytological Observations of the Ovarian Epithelium in Mammals during the Reproductive Cycle" <i>J. Morphol.</i> 150:135-66 (1976)
A2	Auerbach, R. et al. "Expression of Organ-Specific Antigens on Capillary Endothelial Cells" <i>J. Microvasc. Res.</i> 29:401-11 (1985)
A3	Blaustein, Ancel & Lee, Hyun "Surface Cells of the Ovary and Pelvic Peritoneum: A Histochemical and Ultrastructure Comparison" <i>Gyn. Oncol.</i> 8:34-43 (1979)
A4	Cantarow, Walter D. et al. "The Value of Tumor Markers in Cancer of the Ovary" <i>Int. J. Radiation Oncol. Biol. Phys.</i> 7:1095-98 (1981)
A5	Folkman, Judah "Tumor Angiogenesis" <i>Advances in Cancer Research</i> (Klein & Weinhouse eds., Academic Press, New York, 1985) pp. 175-203
A6	Folkman, Judah et al. "Angiogenesis Inhibition and Tumor Regression caused by heparin or a Heparin Fragment in the Presence of Cortisone" <i>Science</i> 221:719-25 (Aug. 19, 1983)
A7	Folkman, Judah et al. "Control of Angiogenesis with Synthetic Heparin Substitutes" <i>Science</i> 243:1490-93 (March 17, 1989)
A8	Folkman, Judah and Shing, Yuen "Angiogenesis" <i>J. Biol. Chem.</i> 267(16):10931-34 (1992)
A9	Genbank Accession No. AAC26082 for GPR39 [Homo sapiens][13-Jul-1998]
A10	Genbank Accession No. AF034633 for Homo sapiens orphan G protein-coupled receptor (GPR39) mRNA, complete cds [13-Jul-1998]
A11	Kudlacek, St. et al. "Use of CA 125 Monoclonal Antibody to Monitor Patients with Ovarian Cancer" <i>Gyn. Onc.</i> 35:323-29 (1989)
A12	McKee, Karen Kulju et al. "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors" <i>Genomics</i> 46(3):426-34 (1997)
A13	Nicosia, Santo V. and Johnson, Joan H. "Surface Morphology of Ovarian Mesothelium (Surface Epithelium) and of Other Pelvic and Extrapelvic Mesothelial Sites in the Rabbit" <i>Int. J. Gynecol. Pathol.</i> 3:249-60 (1983).
A14	Omar, Y.T. et al. "Serum Levels of CA 125 in Patients with Gastrointestinal Cancers" <i>Tumor Biol.</i> 10:316-23 (1989)
A15	Papadaki, Lucienne & Beilby, J.O.W. "The Fine Structure of the Surface Epithelium of the Human Ovary" <i>J. Cell Sci.</i> 8:445-64 (1971)

Examiner

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not consider d. Includ copy of this form with next communication to applicant.

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Galvin, Katherine *et al.*

Serial No.: 09/635,521

Filed: August 9, 2000

For: METHODS AND COMPOSITIONS FOR THE
DIAGNOSIS AND TREATMENT OF
CARDIOVASCULAR AND TUMORIGENIC
DISEASE USING 4941

Attorney Docket No.: MNI-094

Group Art Unit: 1636

Examiner: Loeb, Bronwen

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

August 6, 2002

By:


Maria C. Laccotripe, Ph.D.

Date of Signature and of Mail Deposit

Attorney for Applicants

Limited Recognition Under 37 CFR §10.9(b)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed June 24, 2002 during the prosecution of PCT/US01/13788 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's


consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(1), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application *for the first time* not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Maria C. Laccotripe, Ph.D.
Attorney for Applicants
Limited Recognition Under 37 CFR§10.9(b)

28 State Street
Boston, MA 02109
(617) 227-7400

Date: August 6, 2002

GAD/AEM/MCL/JXS/ham
Enclosures

